{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ARCT",
  "name": "Arcturus Therapeutics Holdings Inc.",
  "url": "https://frontierpicks.com/dossiers/ARCT/",
  "json_url": "https://frontierpicks.com/dossiers/ARCT.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Arcturus Therapeutics’ regained vaccine rights underpin a revaluation thesis that requires ARCT-810 data and a stated regulatory development path by 2026-09-30. Missing that disclosure boundary or a weekly close below $12 invalidates the case.",
  "invalidation_trigger": "A weekly close below $12 invalidates the rights-return revaluation structure; independently, 2026-09-30 passing without ARCT-810 Phase 2 data and a stated regulatory development path breaks the near-term clinical thesis.",
  "catalyst_date": "2026-09-30",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "The ARCT-810 disclosure is guided to quarter-end rather than a fixed event date; September 30 is the boundary of the company’s third-quarter guidance."
  ],
  "body_markdown": "## Current Thesis\n\nArcturus Therapeutics’ regained vaccine rights underpin a revaluation thesis that requires ARCT-810 clinical data and a stated regulatory development path by 2026-09-30. That deadline remains a guidance boundary, not a scheduled announcement: the company’s 2026-08-06 release promised the disclosure during the third quarter. [Q2 release](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm)\n\nSince the 2026-08-30 assessment, attention has gained dated company events while price momentum has moderated. The adjusted reference close was $14.73 on 2026-09-11, versus $15.19 on 2026-08-28; the 14-day relative strength index (RSI) was 56.3 versus 89.6 on those dates. The inference is that the narrative is maturing — September conference appearances have extended the August rights-return story, but the reference close remains below its August 28 reading. The company’s release archive, checked on 2026-09-13, lists its August 31 conference announcement as the latest release; it does not establish what was discussed in individual webcasts. [Release archive](https://ir.arcturusrx.com/press-releases)\n\n## Bull Case\n\n- **Rights returned with financial relief.** The 2026-08-06 settlement disclosure reported global KOSTAIVE and infectious-disease portfolio rights returning alongside $12 million in cash and approximately $16 million in released liabilities and research credits. These are concrete settlement benefits; future commercialization remains unproven. [Q2 release](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm)\n- **Clinical disclosure has a boundary.** On 2026-08-06, Arcturus said ARCT-810 Phase 2 enrollment and dosing were complete and guided data and regulatory plans for the third quarter. Completion supports the disclosure timetable, without establishing efficacy. [Q2 release](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm)\n- **Analyst attention continued into September.** MarketBeat records Roth Capital reiterating its rating with a $41 price target on 2026-09-02. This is Roth’s valuation opinion, not clinical evidence or a dossier price objective. [Analyst record](https://www.marketbeat.com/stocks/NASDAQ/ARCT/forecast/)\n\n## Bear Case\n\n- **Tolerability needs fuller disclosure.** The 2026-08-25 filed symposium poster states that one participant received only four doses because of elevated transaminases, which subsequently resolved without treatment. That observation belongs in the clinical assessment; it does not establish the frequency of liver-related adverse events in a broader population. [Filed poster](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001130/e665725_ex99-1.pdf)\n- **Momentum is weaker than before.** The supplied adjusted series records a $14.73 close and RSI of 56.3 on 2026-09-11, below the corresponding $15.19 and 89.6 readings on 2026-08-28. The longer-window advance therefore does not establish renewed near-term acceleration.\n- **Runway remains management guidance.** The 2026-08-06 release reported $191.5 million of cash and equivalents at 2026-06-30 and projected runway through year-end 2028. The same release placed the ARCT-032 Phase 3 decision in the fourth quarter of 2026. [Q2 release](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm)\n\n## Setup & Price Structure\n\nThe supplied adjusted series shows a three-month price increase of 111.3% through 2026-09-11, while the $14.73 reference close remained 36.4% below the series’ $23.16 trailing-year high. These describe different windows; neither proves a completed base. Moving-average levels and a volume series are missing, so distance above a rising average and participation breadth cannot be assessed.\n\nThe $12 threshold remains the research invalidation published on 2026-08-30. It is not presented as newly verified chart support. A weekly close below $12 ends the price component of the revaluation thesis.\n\nAttention is observable through the company’s September 8, 9 and 10 conference schedule and its upcoming September 15 and 29 appearances, announced on 2026-08-31. That clustering measures corporate exposure, not investor ownership. The available evidence does not establish crowded positioning, insider distribution or issuance into the advance. [Conference announcement](https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-participate-upcoming-investor-conferences)\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-29 — ROTH investor meetings.** The same August 31 announcement confirms meetings, without promising a public clinical disclosure. [Conference announcement](https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-participate-upcoming-investor-conferences)\n- **2026-09-30 — Guided disclosure boundary.** This is quarter-end for the ARCT-810 data and regulatory-plan guidance issued on 2026-08-06, rather than a confirmed event date. [Q2 release](https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_ex99-1.htm)\n\n## Elapsed catalysts\n\n- **2026-09-15 — H.C. Wainwright presentation.** The company’s 2026-08-31 announcement schedules the presentation for 11:30 a.m. Eastern. It provides a public communication opportunity; the announcement does not designate it as the clinical readout. [Conference announcement](https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-participate-upcoming-investor-conferences) *(passed 5d ago)*\n\n## What Would Change Our Mind\n\nFailure to convert the completed ARCT-810 study into disclosed data and a stated regulatory development path by 2026-09-30 breaks the near-term clinical thesis. Independently, a weekly close below $12 invalidates the published price structure. The affirmative case requires the promised disclosure by that boundary, including an identified next regulatory step; conference attendance or an analyst target alone does not satisfy it.\n\nConviction remains low because the August 6 guidance establishes timing, while the August 25 poster observation leaves tolerability questions for the fuller disclosure. A reliable clinical success probability cannot be inferred from those disclosures alone.\n\n## Correlation Notes\n\nThis remains a single-company clinical setup. The 2026-08-20 coverage of Moderna and Merck’s messenger RNA vaccine research documents attention to the broader technology, but it supplies no ARCT-810 efficacy evidence. No paired return series is available to quantify ARCT’s correlation with Moderna or biotechnology indices; shared technology does not establish shared price behavior.",
  "first_seen": "2026-08-20",
  "last_analyzed": "2026-09-13T00:51:55+00:00",
  "last_synthesized": "2026-09-13",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}